alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['F617L'],"[{'ncitCode': 'C115977', 'drugName': 'Larotrectinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['30624546', '31738426']","[{'link': 'https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf', 'abstract': 'Drilon et al. Abstract# 4000, AACR 2019.'}]","Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. NTRK3 F617L is listed in the FDA label for larotrectinib as a resistance mutation. At least one patient with an NTRK-fusion-positive tumor acquired an NTRK3 F617L mutation upon progression on larotrectinib (PMID: 31738426, 30624546). This mutation is considered a gatekeeper residue (Abstract: Drilon et al. Abstract# 4000, AACR 2019. https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf)."
